Hidden influenza vulnerability found in human antibodies
17 May 2019 | By Drug Target Review
Scientists have discovered an unexpected weakness in the influenza virus protein.
List view / Grid view
Drug Leads
Fast molecular interaction screening for all your projects
21 March 2019 | By NanoTemper Technologies
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
19 March 2019 | By Aparajita Dubey - Associate Consultant at Prescient Healthcare Group
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…
Targeting innate immunity to treat disease: potential therapeutic applications
3 December 2018 | By Christopher Schaber - PhD, Oreola Donini - PhD - Chief Scientific Officer, President - Chief Executive Officer, Richard Straube - MD - Chief Medical Officer
Despite being one of the more ancient aspects of immunity, therapeutic modulation of the innate immune system has rarely been attempted. Innate immunity is intrinsically linked to the generation of inflammation – necessary for signalling to the adaptive immune system but often self-perpetuating and over-exaggerated, leading to deleterious effects, including…
slincR gene could shed light on chemical exposure effects in humans
26 November 2018 | By Drug Target Review
The discovery of a new gene in zebrafish could lead to a better understanding of how exposure to chemicals leads to disease in humans...
Cyclic peptoids show promise as prostate cancer drug
25 October 2018 | By Drug Target Review
Scientists in the U.S. have developed molecules, termed cyclic peptoids, that block the action of genes that drive the growth of therapy-resistant prostate cancer, according to a new study.
PD-1 and CTLA4 therapies together could benefit women with ovarian cancer
20 September 2018 | By Iqra Farooq (Drug Target Review)
Women with ovarian cancer could in future benefit from a combined therapy using PD-1 and CTLA-4 as shown through the results of this Phase II trial...
Six compounds identified from 70,000 to help eradicate malaria
18 September 2018 | By Iqra Farooq (Drug Target Review)
Researchers from Imperial College London have identified 6 compounds from almost 70,000 that could help to eradicate malaria...
A new generation of pain relief
10 September 2018 | By Drug Target Review
Researchers have developed a new generation of pain relief drugs that only target the affected area, with the help of computer simulations...
Compound with selectivity for cancer cells without p53 identified
20 August 2018 | By Iqra Farooq (Drug Target Review)
The compound has been shown to target cancer cells without the p53 gene, and does not affect healthy cells...
Potential peptide drug could treat liver cancer effectively
2 August 2018 | By Drug Target Review
Researchers have discovered that FFW and Sorafenib used together could reduce the growth of Sorafenib resistant hepatocellular carcinoma tumours...
Monoclonal antibodies produced by new cell lines hope to improve drugs
1 August 2018 | By Drug Target Review
Many biopharmaceutical companies look to produce biosimilars soon, since the patents on the original mAb expire over the next few years...
CBD improves survival rates of mice with pancreatic cancer
31 July 2018 | By Dr Zara Kassam (Drug Target Review)
Mice with pancreatic cancer that were treated with CBD alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone...
Progress toward improved Wilson’s disease drug
28 June 2018 | By Drug Target Review
Researchers have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease...
Experimental drug combined with radiation extends the survival of GBM
28 June 2018 | By Drug Target Review
A new study has shown that an experimental drug known as AZ32 significantly extends the survival of glioblastoma multiforme, the most common and deadly form of brain cancer...
Follow: